{
    "organizations": [],
    "uuid": "0217ce5573de16e49acff539f84c27102e9e5629",
    "author": "",
    "url": "https://www.reuters.com/article/brief-fibrocell-announces-fda-allowance/brief-fibrocell-announces-fda-allowance-to-initiate-pediatric-enrollment-in-phase-1-2-clinical-trial-of-fcx-007-idUSASB0C2Z2",
    "ord_in_thread": 0,
    "title": "BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 13 PM / in 11 minutes BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007 Reuters Staff 1 Min Read \nJan 30 (Reuters) - Fibrocell Science Inc: \n* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) \n* FIBROCELL SCIENCE INC - FCX-007, COâ€˜S GENE THERAPY CANDIDATE, IS BEING DEVELOPED IN COLLABORATION WITH INTREXON CORPORATION  ",
    "published": "2018-01-30T15:13:00.000+02:00",
    "crawled": "2018-01-30T15:32:14.022+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "announces",
        "fda",
        "allowance",
        "initiate",
        "pediatric",
        "enrollment",
        "phase",
        "clinical",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "fibrocell",
        "science",
        "inc",
        "fibrocell",
        "announces",
        "fda",
        "allowance",
        "initiate",
        "pediatric",
        "enrollment",
        "phase",
        "clinical",
        "trial",
        "treatment",
        "recessive",
        "dystrophic",
        "epidermolysis",
        "bullosa",
        "rdeb",
        "fibrocell",
        "science",
        "inc",
        "co",
        "gene",
        "therapy",
        "candidate",
        "developed",
        "collaboration",
        "intrexon",
        "corporation"
    ]
}